| Contributors: |
Mandoli, G. E.; Pastore, M. C.; Giannoni, A.; Benfari, G.; Dini, F. L.; Rosa, G.; Pugliese, N. R.; Taddei, C.; Correale, M.; Brunetti, N. D.; Mazzeo, P.; Carluccio, E.; Mengoni, A.; Guaricci, A. I.; Piscitelli, L.; Citro, R.; Ciccarelli, M.; Novo, G.; Corrado, E.; Pasquini, A.; Loria, V.; De Carli, G.; Degiovanni, A.; Patti, G.; Santoro, C.; Moderato, L.; Cicoira, M.; Canepa, M.; Malagoli, A.; Emdin, M.; Cameli, M. |
| Description: |
Aims: Sacubitril/valsartan has changed the treatment of heart failure with reduced ejection fraction (HFrEF), due to the positive effects on morbidity and mortality, partly mediated by left ventricular (LV) reverse remodelling (LVRR). The aim of this multicenter study was to identify echocardiographic predictors of LVRR after sacubitril/valsartan administration. Methods and results: Patients with HFrEF requiring therapy with sacubitril/valsartan from 13 Italian centres were included. Echocardiographic parameters including LV global longitudinal strain (GLS) and global peak atrial longitudinal strain by speckle tracking echocardiography were measured to find the predictors of LVRR [=LV end-systolic volume reduction ≥10% and ejection fraction (LVEF) improvement ≥10% at follow-up] at 6month follow-up as the primary endpoint. Changes in symptoms [New York Heart Association (NYHA) class] and neurohormonal activations [N-terminal pro-brain natriuretic peptide (NT-proBNP)] were also evaluated as secondary endpoints; 341 patients (excluding patients with poor acoustic windows and missing data) were analysed (mean age: 65±10years; 18% female, median LVEF 30% [inter-quartile range: 25−34]). At 6month follow-up, 82 (24%) patients showed early complete response (LVRR and LVEF≥35%), 55 (16%) early incomplete response (LVRR and LVEF |